TNFRSF8 and diffuse large B-cell lymphoma: A phase II study, evaluating the efficacy of brentuximab-vedotin in relapsed/refractory CD30- expressing NHL, showed significant activity as single-agent in relapsed/refractory DLBCL with an ORR of 44 %, CR of 17 % and with a median duration of 16.6 months thus far [432] (Additional file 1: Table S7).